Last reviewed · How we verify
Spironolacton (hexalacton(R))
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that blocks aldosterone receptors in the collecting duct of the kidney to reduce sodium reabsorption and increase potassium retention.
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that blocks aldosterone receptors in the collecting duct of the kidney to reduce sodium reabsorption and increase potassium retention. Used for Heart failure with reduced ejection fraction, Hypertension, Primary hyperaldosteronism.
At a glance
| Generic name | Spironolacton (hexalacton(R)) |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Potassium-sparing diuretic; aldosterone antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone competitively inhibits aldosterone at mineralocorticoid receptors, preventing sodium and water reabsorption while promoting potassium retention. This dual action reduces blood volume and blood pressure while preserving serum potassium levels. It is commonly used in heart failure, hypertension, and hyperaldosteronism management.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Primary hyperaldosteronism
- Edema associated with cirrhosis or nephrotic syndrome
Common side effects
- Hyperkalemia
- Gynecomastia
- Menstrual irregularities
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolacton (hexalacton(R)) CI brief — competitive landscape report
- Spironolacton (hexalacton(R)) updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI